- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01253018
Evaluation of Robot Assisted Neuro-Rehabilitation (SRT3)
Evaluation of Robot Assisted Neuro-rehabilitation
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
After obtaining informed consent, participants will undergo 3 sessions of baseline testing using upper extremity motor assessments of the shoulder, elbow, wrist, thumb and grip. Upper extremity kinematic and strength testing will be performed with the rehabilitation robots in measurement mode. The rehabilitation robot modules include the wrist, the planar (shoulder-elbow), and alternating wrist and shoulder-elbow robot. These robotic devices are cleared for marketing as a registered medical device under U.S. FDA regulations and are listed with the FDA both as an evaluation devices and as therapy devices.
Patients will be randomized to receive 12 weeks of robotic therapy sessions or 12 weeks of robot therapy combined with transition to task therapy. Study interventions will occur 3 times a week for 12 weeks. Robot therapy will consist of a progression through three robot modules: wrist, planar, and alternating wrist and shoulder-elbow robot. The progression will be sequential with four weeks of training on each robotic device. All participants will complete a motor activity log during this intervention phase.
TMS is being used for physiological measurement and evaluations will be conducted with each participant at baseline, week one, week five, eight, and final. TMS will also occur during the follow-up on week twenty-four.
Disability and depression questionnaires, upper extremity measures and evaluations of functional performance will be conducted during the study at baseline, and at training completion (visit 36). Patients will return twelve weeks after the end of the training period to determine whether any observed improvements persist.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other possible diagnoses
- Adequate language, and cognitive function to participate in training, testing, and informed consent process
- The study arm of the participant will present with moderate to severe dysfunction based on Fugl-Meyer Motor Assessment range of 7 to 38
- Stroke onset greater than 6 months for ischemic stroke and greater than 1 year for hemorrhagic stroke
- Men or women over 21 years of age
Exclusion Criteria:
- Seizures or treatment with anticonvulsant medications within the last 10 years (This criteria does not preclude participation in the study, but does preclude participation in the TMS testing)
- Treatment with any medications known to interfere with brain stimulation: any medication with central nervous system depressant activity, including, but not limited to benzodiazepines, barbiturates, and neuroleptics (This criteria does not preclude participation in the study, but does preclude participation in the TMS testing)
- Serious complicating medical conditions, contractures or orthopedic problems in the study arm limiting the range of joint movement for the study positions
- Visual loss such that the participant cannot see the test patterns on the monitor of the training robot computer
- Botox injection to the study arm within 3 months of enrollment or during the study period
- Any change in the exercise regime involving the study arm. This includes starting any new exercise or discontinuing any current exercise regimen
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Robot Therapy
12 weeks of robotic therapy
|
Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
Autres noms:
|
|
Comparateur actif: Transition to Task Training
12 weeks of task specific practice combined with robotic therapy
|
Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fugl-Meyer Motor Upper Extremity Assessment
Délai: Baseline, 12 week, and 24 week retention
|
This is a stroke-specific measure of impairment of the upper extremity that has been shown to be valid and reliable with high inter-rater and test-retest reliability.
It provides a direct-observational assessment of volitional movement and motor impairment related to reflexes, sensation, and abnormal synergies.
Each item on the FM is rated on a three-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully).
The scale ranges from 0-66 with higher scores representing less motor impairment.
|
Baseline, 12 week, and 24 week retention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Motor Cortex Excitability Via Transcranial Magnetic Stimulation (TMS)
Délai: week 12
|
week 12
|
|
|
Wolf Motor Function Test (WMFT)
Délai: Baseline, 12 week, and 24 week retention
|
The Wolf Motor Function Test (WMFT) examines UE function based on task performance time, quality of movement, and ability to hold a weight.
Functional use and speed of movement are based on fifteen timed activities and two strength activities.
It has high inter-rater reliability, internal consistency, and test-retest reliability.
Timed tasks that cannot be completed default to a time score of 120 seconds.
Faster times or a lower score in seconds represent better function.
Improvement is represented by a decreased time to complete the tasks therefore a negative change score from baseline to follow-up indicates improvement.
|
Baseline, 12 week, and 24 week retention
|
|
Stroke Impact Scale: Hand Subscale
Délai: Baseline, 12 week and 24 week retention
|
The Stroke Impact Scale (SIS) is a self-report structured interview consisting of eight domains designed to assess changes in impairment, disabilities, and handicap following stroke that contribute to quality of life.
It has been tested and found to be reliable, valid, and sensitive to change in the stroke population.
There are four physical domains that that can be analyzed separately.
The hand domain was analyzed for this study and the scores for this domain range from 0-100.
Higher scores indicate greater function.
|
Baseline, 12 week and 24 week retention
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christopher T. Bever, MD, Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- B6935-R
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .